Ventricular arrhythmia incidence rates in acalabrutinib users vs ibrutinib and non–BTKi-treated populations. VA crude (A) and cumulative (B∗∗) incidence rates in acalabrutinib users vs ibrutinib and non–BTKi-treated populations, respectively. ∗Those without prior ibrutinib or structural heart disease. ∗∗Assumes a linear event rate over time.